ClinicalTrials.gg
RecruitingNCT07263919Updated Dec 31, 2025

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

A Phase 2 interventional study of Cadonilimab (AK104) and Cisplatin in Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma, sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Planned enrollment
146th of 351
90 · median 70
Started
2025
with 30 others
Phase 2
212 of 401
96 open now
Primary completion
2030-03
later than 205 of 212 live
Registered
342nd of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 146th largest by planned enrollment of the 351 interventional ones that give a count, is one of 31 that started in 2025, is one of 212 in phase 2, reaches primary completion later than 205 of the 212 other live ones, and was the 342nd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

169 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of perioperative Cadonilimab combined with neoadjuvant chemotherapy versus neoadjuvant chemotherapy in patients with resectable ESCC.

03

Conditions studied

  • Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be able and willing to provide written and to comply with all requirements of study participation (including all study procedures).
  • ≥18 years old and ≤ 75 years (regardless of sex).
  • confirmed esophageal squamous cell carcinoma, assessed as resectable.
  • Adequate pulmonary function.
  • Adequate tumor tissue samples.
  • performance status of 0-1.
  • Adequate organ function.
  • Within 7 days prior to the first dose, women of must have a negative urine or serum pregnancy test and agree to use effective during the study treatment period and for 120 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Presence of suspected distant lesions, or locally advanced unresectable disease.
  • confirmed as other pathological types.
  • Previous surgery precludes the use of gastric substitution for esophageal reconstruction in the current procedure.
  • History of other malignant tumors within the past 5 years.
  • Within 4 weeks prior to randomization, presence of conditions such as severe esophagogastric varices, active ulcers, unhealed wounds, gastrointestinal perforation, or intestinal obstruction.
  • Active or documented history of inflammatory bowel disease.
  • Clinically symptomatic or recurrent pleural, pericardial, or ascitic fluid requiring drainage.
  • Uncontrolled concurrent illnesses.
  • Acute exacerbation of within 4 weeks prior to randomization.
  • History of myocardial infarction, unstable angina, congestive heart failure within 12 months prior to day 1 of study treatment.
  • History of severe bleeding tendency or coagulation dysfunction.
  • Arterial thromboembolic events within 6 months prior to randomization.
  • History or current presence of non-infectious pneumonitis/interstitial lung disease requiring systemic .
  • Known psychiatric disorders, drug abuse, or substance addiction.
  • Pregnant or lactating women.
  • Prior systemic or local antitumor therapy for locally advanced esophageal squamous cell carcinoma.
  • Systemic non-specific immunomodulatory therapy within 2 weeks prior to randomization.
  • Major surgery or severe trauma within 4 weeks prior to randomization.
  • Known allergy to any component of the drug(s).
  • Active disease requiring systemic treatment within 2 years prior to randomization.
  • Active infection.
  • Known active tuberculosis.
  • Severe infections within 4 weeks prior to randomization.
  • History of immunodeficiency or positive test.
  • Known active syphilis infection.
  • within 4 weeks prior to randomization or planned during the study.
  • History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  • Is currently participating in a study of an investigational agent or using an investigational device.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Cadonilimab (dose 1) combined with Cisplatin and Paclitaxel

    Drug: Cadonilimab (AK104) · Drug: Cisplatin · Drug: Paclitaxel

  • Experimental
    Cadonilimab (dose 2) combined with Cisplatin and Paclitaxel

    Drug: Cadonilimab (AK104) · Drug: Cisplatin · Drug: Paclitaxel

  • Active comparator
    Cisplatin and Paclitaxel

    Drug: Cisplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response (pCR) rate as assessed by the investigator

    Proportion of subjects with no tumor residue in the primary tumor and regional lymph nodes.

    Time frame: Up to approximately 2 years

  2. Adverse Event (Phase II stage)

    Incidence and severity of adverse events (AEs), rate of delayed surgery, and clinically significant abnormal laboratory findings.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Major Pathological Response (MPR) rate as assessed by the investigator

    Proportion of subjects with ≤10% residual live tumor cells as assessed by the investigator.

    Time frame: Up to approximately 2 years

  2. R0 resection rate

    Proportion of subjects with pathologically complete resection of primary tumors

    Time frame: Up to approximately 2 years

  3. Event Free Survival (EFS)

    Time from randomization until radiographic disease progression, local progression precluding surgery, inability to resect the tumor, local or distant recurrence, or death due to any cause.

    Time frame: Up to approximately 5 years

  4. Disease Free Survival (DFS)

    Time from surgery to local or distant recurrence, or death due to any cause.

    Time frame: Up to approximately 5 years

  5. Overall Survival (OS)

    Time from randomization until death from any cause.

    Time frame: Up to approximately 5 years

  6. Overall Response Rate (ORR)

    Proportion of subjects with complete response (CR) or partial response (PR) during the neoadjuvant stage.

    Time frame: Up to approximately 2 years

  7. Disease Control Rate (DCR)

    Evaluation of DCR based on RECIST v1.1

    Time frame: Up to approximately 2 years

  8. Pharmacokinetics (PK)

    PK parameters: serum concentrations of Cadonilimab at different point of time

    Time frame: Up to approximately 2 years

  9. Anti-Drug Antibodies(ADAs)

    Proportion of subjects with detectable ADA.

    Time frame: Up to approximately 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2030, 51 months after the start.

Of 173 phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 4, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Mar 2030
CompletionEst.
Dec 2031
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07263919
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Dec 19, 2025
Primary completion
Mar 2030 (estimated)
Completion
Dec 2031 (estimated)
Last update
Dec 31, 2025

Study contacts

Wenting Li
Contact
wenting01.li@akesobio.com
18116403289
Xiaolong Yan
principal investigator · The Second Affiliated Hospital of Air Force Military Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion